SPOTLIGHT: Roche to mount big diabetes push


Roche is putting new emphasis on its diabetes business by drawing a new line on its org chart, straight from diabetes chief Burkhard Piper to CEO presumptive Severin Schwan. Piper will report directly to Schwan, along with the heads of Roche's pharma and diagnostics divisions. It's evidence of a new commitment to the diabetes business--understandable, considering the number of patients is expected to skyrocket in coming years. Report

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.